Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma

O. Slaby, J. Srovnal, L. Radova, J. Gregar, J. Juracek, P. Luzna, M. Svoboda, M. Hajduch, J. Ehrmann,

. 2015 ; 36 (5) : 521-527. [pub] 20150316

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15031427

Grantová podpora
NT13585 MZ0 CEP - Centrální evidence projektů

Esophageal adenocarcinoma (EAC) is highly aggressive malignancy that frequently develops from Barrett's esophagus (BE), a premalignant pathologic change occurring in the lower end of the esophagus. MicroRNAs (miRNAs) are small, non-coding RNAs that function as posttranscriptional regulators of gene expression and were repeatedly proved to play key roles in pathogenesis of BE as well as EAC. In our study, we used Affymetrix GeneChip miRNA arrays to obtain miRNA expression profiles in total of 119 tissue samples [24 normal esophageal mucosa (EM), 60 BE and 35 EAC]. We identified a number of miRNAs, that showed altered expression progressively in sequence EM, BE and EAC, including for instance miR-21, miR-25, miR-194 and miR-196a with increasing levels (P < 0.0015) and miR-203, miR-205, miR-210 and miR-378 with decreasing levels (P < 0.0001). The subsequent analysis revealed four diagnostic miRNA signatures enabling to distinguish EM and BE [12 miRNAs, area under curve (AUC) = 0.971], EM and EAC (13 miRNAs, AUC = 1.0), BE without and BE with dysplasia (21 miRNAs, AUC = 0.856) and BE without dysplastic changes and BE with dysplasia together with EAC (2 miRNAs, AUC = 0.886). We suggest that miRNA expression profiling expands current knowledge in molecular pathology of Barrett's-based carcinogenesis and enables identification of molecular biomarkers for early detection of BE dysplasia and progression to EAC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031427
003      
CZ-PrNML
005      
20170525101545.0
007      
ta
008      
151005s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/carcin/bgv023 $2 doi
035    __
$a (PubMed)25784377
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Slabý, Ondřej, $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Masaryk University, Faculty of Medicine, 656 53 Brno, Czech Republic, Central European Institute of Technology, Molecular Oncology II, Masaryk University, 625 00 Brno, Czech Republic, on.slaby@gmail.com. $d 1981- $7 js20030220015
245    10
$a Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma / $c O. Slaby, J. Srovnal, L. Radova, J. Gregar, J. Juracek, P. Luzna, M. Svoboda, M. Hajduch, J. Ehrmann,
520    9_
$a Esophageal adenocarcinoma (EAC) is highly aggressive malignancy that frequently develops from Barrett's esophagus (BE), a premalignant pathologic change occurring in the lower end of the esophagus. MicroRNAs (miRNAs) are small, non-coding RNAs that function as posttranscriptional regulators of gene expression and were repeatedly proved to play key roles in pathogenesis of BE as well as EAC. In our study, we used Affymetrix GeneChip miRNA arrays to obtain miRNA expression profiles in total of 119 tissue samples [24 normal esophageal mucosa (EM), 60 BE and 35 EAC]. We identified a number of miRNAs, that showed altered expression progressively in sequence EM, BE and EAC, including for instance miR-21, miR-25, miR-194 and miR-196a with increasing levels (P < 0.0015) and miR-203, miR-205, miR-210 and miR-378 with decreasing levels (P < 0.0001). The subsequent analysis revealed four diagnostic miRNA signatures enabling to distinguish EM and BE [12 miRNAs, area under curve (AUC) = 0.971], EM and EAC (13 miRNAs, AUC = 1.0), BE without and BE with dysplasia (21 miRNAs, AUC = 0.856) and BE without dysplastic changes and BE with dysplasia together with EAC (2 miRNAs, AUC = 0.886). We suggest that miRNA expression profiling expands current knowledge in molecular pathology of Barrett's-based carcinogenesis and enables identification of molecular biomarkers for early detection of BE dysplasia and progression to EAC.
650    _2
$a adenokarcinom $x genetika $x patologie $7 D000230
650    _2
$a senioři $7 D000368
650    _2
$a Barrettův syndrom $x genetika $x patologie $7 D001471
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a progrese nemoci $7 D018450
650    _2
$a nádory jícnu $x genetika $x patologie $7 D004938
650    _2
$a ezofágus $x metabolismus $x patologie $7 D004947
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    12
$a stanovení celkové genové exprese $7 D020869
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů $7 D020411
650    _2
$a prognóza $7 D011379
650    _2
$a ROC křivka $7 D012372
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a nádorové biomarkery $x genetika $7 D014408
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Srovnal, Josef $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic. $7 xx0091239
700    1_
$a Radová, Lenka $u Central European Institute of Technology, Molecular Oncology II, Masaryk University, 625 00 Brno, Czech Republic. $7 xx0092752
700    1_
$a Gregar, Jan $u Department of Internal Medicine II - Gastroenterology and Hepatology, University Hospital, 779 00 Olomouc, Czech Republic and. $7 xx0149630
700    1_
$a Juráček, Jaroslav $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Masaryk University, Faculty of Medicine, 656 53 Brno, Czech Republic, Central European Institute of Technology, Molecular Oncology II, Masaryk University, 625 00 Brno, Czech Republic. $7 xx0165783
700    1_
$a Lužná, Pavla, $u Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 779 00 Olomouc, Czech Republic. $d 1983- $7 xx0165786
700    1_
$a Svoboda, Marek, $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Masaryk University, Faculty of Medicine, 656 53 Brno, Czech Republic, Central European Institute of Technology, Molecular Oncology II, Masaryk University, 625 00 Brno, Czech Republic. $d 1975- $7 xx0098478
700    1_
$a Hajdúch, Marián, $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic. $d 1969- $7 xx0050218
700    1_
$a Ehrmann, Jiří, $u Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 779 00 Olomouc, Czech Republic. $d 1967- $7 jo2003163162
773    0_
$w MED00001050 $t Carcinogenesis $x 1460-2180 $g Roč. 36, č. 5 (2015), s. 521-527
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25784377 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20170525101943 $b ABA008
999    __
$a ok $b bmc $g 1092303 $s 914553
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 36 $c 5 $d 521-527 $e 20150316 $i 1460-2180 $m Carcinogenesis $n Carcinogenesis $x MED00001050
GRA    __
$a NT13585 $p MZ0
LZP    __
$a Pubmed-20151005

Najít záznam

Citační ukazatele

Možnosti archivace